Pfizer raises full-year outlook on strong anticoagulant, cancer drug sales
Pfizer raised its full-year outlook. The supplied report says anticoagulant and cancer drug performance was strong.
Related stories
Soybeans Near 3-Month Low on Ample Supply Outlook
Soybean futures fell around $11.9 per bushel, approaching their lowest level in three months, as expectations of abundant global supplies and concerns over Chinese demand weighed o
L impact | EARNINGS | Nov 04, 2026, 02:40 AM UTC
Taco Bell Q3 sales fall more than expected amid illness
Yum Brands said Taco Bell sales fell more than expected in the third quarter amid illness; sales are recovering this quarter.
L impact | EARNINGS | Nov 04, 2026, 02:38 AM UTC
PainChek Reports A$1.210 Million September-Quarter Customer Revenue
L impact | EARNINGS | Nov 04, 2026, 02:36 AM UTC
Sumitomo Bakelite Reports Six-Month Pretax Profit Up 52.7%
M impact | EARNINGS | Nov 04, 2026, 02:30 AM UTC
Sumitomo Bakelite Reports Six-Month Operating Profit
Group operating profit rose 57.9%; its 2026/27 forecast profit is up 40.9%.
M impact | EARNINGS | Nov 04, 2026, 02:30 AM UTC
Sumitomo Bakelite Reports Six-Month Net Profit Growth
Group IFRS net profit rose 47.2%; the company forecast 2026/27 profit growth of 24.9%.
M impact | EARNINGS | Nov 04, 2026, 02:30 AM UTC